Dr. Eric Biron, PhD, is a Regular Researcher at the CHU de Québec Research Center and Full Professor at the Faculty of Pharmacy of Laval University. Recognized for his contributions in peptide chemistry, combinatorial chemistry and antimicrobial peptides, Dr. Biron is particularly interested in the use of peptidomimetic macrocycles and heterocycles in medicinal chemistry. His research focuses on the discovery and development of novel therapeutic agents for the treatment of infectious diseases and cancers.

Discovery and development of new antibacterial agents

The alarming spread of antibiotic resistance has become a major problem in the treatment of bacterial infections. In this context, Dr. Biron is particularly interested in bacteriocins, a family of low molecular weight proteins produced by several bacteria, with strong antimicrobial activity. As they exhibit inhibitory activities against a large number of clinically important pathogenic bacteria, bacteriocins are increasingly considered as a promising substitute to antibiotics.

Based on their enormous potential in the pharmaceutical and medical areas, Dr. Biron’s laboratory is developing novel synthetic approaches to produce bacteriocins, and uses peptidomimetic strategies to optimize their pharmacological properties, improve their pharmacokinetic profile, and modify their spectrum of activity.

Development of new anti-cancer agents

Despite the progress made in various therapeutic approaches, the effectiveness of main anti-cancer therapies has reached a critical plateau in the treatment of several cancers. As a result, the demand for innovative and effective compounds with new modes of action is growing rapidly. In this context, Dr. Biron’s laboratory uses combinatorial chemistry to prepare libraries with high molecular diversity and perform target-based or phenotypic screenings to discover promising anti-cancer molecules.

In another approach, Dr. Biron is interested in the addiction of cancer cells to some multifunctional proteins that also play an important role in the resistance to treatment. In this case, Dr. Biron’s laboratory aims to develop functional inhibitors of these proteins through rational design, and peptidomimetic approaches.

CHUL
2705, boulevard Laurier
T4-50
Québec, Québec
Canada G1V 4G2
49 entries « 1 of 5 »

García-Vela S, Guay LD, Rahman MRT, Biron E, Torres C, Fliss I

Antimicrobial Activity of Synthetic Enterocins A, B, P, SEK4, and L50, Alone and in Combinations, against Clostridium perfringens

Journal Article

Int J Mol Sci, 25 (3), 2024.

Abstract | Links:

Bérubé C, Guay LD, Fraser T, Lapointe V, Cardinal S, Biron É

Convenient route to Fmoc-homotyrosine via metallaphotoredox catalysis and its use in the total synthesis of anabaenopeptin cyclic peptides

Journal Article

Org Biomol Chem, 21 (45), 2023.

Abstract | Links:

Rahman MRT, Fliss I, Biron E

Insights in the Development and Uses of Alternatives to Antibiotic Growth Promoters in Poultry and Swine Production

Journal Article

Antibiotics (Basel), 11 (6), 2022.

Abstract | Links:

Soltani S, Boutin Y, Couture F, Biron E, Subirade M, Fliss I

In vitro assessment of skin sensitization, irritability and toxicity of bacteriocins and reuterin for possible topical applications

Journal Article

Sci Rep, 12 (1), 2022.

Abstract | Links:

Soltani S, Biron E, Ben Said L, Subirade M, Fliss I

Bacteriocin-Based Synergetic Consortia: a Promising Strategy to Enhance Antimicrobial Activity and Broaden the Spectrum of Inhibition

Journal Article

Microbiol Spectr, 10 (1), 2022.

Abstract | Links:

Soltani S, Couture F, Boutin Y, Ben Said L, Cashman-Kadri S, Subirade M, Biron E, Fliss I

In vitro investigation of gastrointestinal stability and toxicity of 3-hyrdoxypropionaldehyde (reuterin) produced by Lactobacillus reuteri

Journal Article

Toxicol Rep, 8 , 2021.

Abstract | Links:

Soltani S, Hammami R, Cotter PD, Rebuffat S, Said LB, Gaudreau H, Bédard F, Biron E, Drider D, Fliss I

Bacteriocins as a new generation of antimicrobials: toxicity aspects and regulations

Journal Article

FEMS Microbiol Rev, 45 (1), 2021.

Abstract | Links:

Vézina-Dawod S, Perreault M, Guay LD, Gerber N, Gobeil S, Biron E

Synthesis and biological evaluation of novel 1,4-benzodiazepin-3-one derivatives as potential antitumor agents against prostate cancer

Journal Article

Bioorg Med Chem, 45 , 2021.

Abstract | Links:

Soltani S, Zirah S, Rebuffat S, Couture F, Boutin Y, Biron E, Subirade M, Fliss I

Gastrointestinal Stability and Cytotoxicity of Bacteriocins From Gram-Positive and Gram-Negative Bacteria: A Comparative in vitro Study

Journal Article

Front Microbiol, 12 , 2021.

Abstract | Links:

Picard M, Robitaille G, Karam F, Daigle JM, Bedard F, Biron E, Tardif MR, Lacombe-Barrios J, Begin P

Cross-Reactivity to Cephalosporins and Carbapenems in Penicillin-Allergic Patients: Two Systematic Reviews and Meta-Analyses

Journal Article

J Allergy Clin Immunol Pract, 7 (8), 2019.

Abstract | Links:

49 entries « 1 of 5 »
Signaler des ajouts ou des modifications

Active projects

  • Dérivatisation de triterpènes naturels par réactions multicomposantes pour le développement de nouveaux composés bioactifs biosourcés, from 2023-08-15 to 2027-08-14
  • Étude des propriétés pharmacocinétiques de nouveaux dérivés de triterpènes biosourcés pour le contrôle de parasites protozoaires , from 2023-12-11 to 2024-12-11
  • Exploiter l'addiction des bactéries au fer: Conception de nouvelles molécules hybrides bactériocine-sidérophore et évaluation de leur potentiel comme alternative aux antibiotiques, from 2021-04-01 to 2024-03-31
  • Institut sur la nutrition et les aliments fonctionnels (INAF), from 2017-04-01 to 2024-03-31
  • New approaches for the design and synthesis of heterocyclic and macrocyclic bioactive peptidomimetics, from 2020-04-01 to 2025-03-31
  • Valorisation de rejets de l'industrie forestière en molécules prometteuses pour le traitement de la malaria, from 2023-10-19 to 2024-03-31

Recently finished projects

  • Design et synthèse d'acides aminés biosourcés pour la préparation de nouveaux triterpènes fonctionnalisés et de peptides conjugés, from 2020-01-13 to 2022-03-12
  • Développement de nouvelles molécules bioactives et d’acides aminés biosourcés par dérivatisation de triterpènes naturels, from 2022-05-01 to 2023-06-30
  • La conception de nouveaux agents thérapeutiques et la résonance magnétique nucléaire, from 2022-01-01 to 2023-05-31
  • Laboratoire de pointe en chimie peptidique et biomoléculaire pour la découverte et la conception de molécules bioactives, from 2022-04-01 to 2023-09-28
  • Valorisation de triterpènes naturels par dérivatisation pour le développement de nouvelles molécules bioactives biosourcées, from 2021-11-15 to 2022-11-14
Data provided by the Université Laval research projects registery